Abstract:Excessive eIF4E phosphorylation by mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (MNK1 and MNK2; collectively, MNKs) has been associated with oncogenesis. The overexpression of eIF4E in acute myeloid leukemia (AML) is related to cancer cell growth and survival. Thus, the inhibition of MNKs and eIF4E phosphorylation are potential therapeutic strategies for AML. Herein, a structure-based virtual screening approach was performed to identify potential MNK inhibitors from natural products. Three flavonoids, apigenin, hispidulin, and luteolin, showed MNK2 inhibitory activity with IC<sub>50</sub> values of 308, 252, and 579 nM, respectively. A structure–activity relationship analysis was performed to disclose the molecular interactions. Furthermore, luteolin exhibited substantial inhibitory efficacy against MNK1 (IC<sub>50</sub> = 179 nM). Experimental results from cellular assays showed that hispidulin and luteolin inhibited the growth of MOLM-13 and MV4-11 AML cells by downregulating eIF4E phosphorylation and arresting the cell cycle at the G0/G1 phase. Therefore, hispidulin and luteolin showed promising results as lead compounds for the potential treatment for AML.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jnatprod.0c00516?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jnatprod.0c00516</a>.Framework for the identification of MNK inhibitors; confirmation of docking protocol by redocking the cocrystallized ligand; the chemical structures of flavonoids that were requested from NCI, NIH, and of in-house flavonoid derivatives; Activity Atlas model of compounds in MNK2; inhibition activity of hispidulin and luteolin against a panel of representative kinases; effects of hispidulin and luteolin on cell cycle progression in AML cell lines; MNK1 and MNK2 inhibition activities of flavonoid derivatives (<a class="ext-link" href="/doi/suppl/10.1021/acs.jnatprod.0c00516/suppl_file/np0c00516_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Progress in developing MNK inhibitors

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

Using Imidazo[2,1-b][1,3,4]thiadiazol Skeleton to Design and Synthesize Novel MNK Inhibitors.

Design, Synthesis and Activity of Mnk1 and Mnk2 Selective Inhibitors Containing Thieno[2,3-D]pyrimidine Scaffold.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases

Design, synthesis and biological evaluation of MNK-PROTACs

MNK: A Novel Promising Target for Cancer Immunotherapy

Selective and Effective Suppression of Pancreatic Cancer Through MNK Inhibition.

Biological Evaluation of Selected Flavonoids as Inhibitors of MNKs Targeting Acute Myeloid Leukemia

Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.

Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy

Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2- d ]pyrimidine derivatives as Mnk1/2 inhibitors

MNK1/2 Inhibition Limits Oncogenicity and Metastasis of KIT-mutant Melanoma

Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors

Progress and Development in Research of Mitotic Kinases Inhibitors

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Design, Synthesis and Evaluation of Novel Phorbazole C Derivatives as MNK Inhibitors through Virtual High-Throughput Screening

MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma

The Overview of Mitogen-activated Extracellular Signal-Regulated Kinase (Mek)-Based Dual Inhibitor in the Treatment of Cancers.

Developments in Mitogen-Induced Extracellular Kinase 1 Inhibitors and Their Use in the Treatment of Disease

Optimization of 4,6-Disubstituted Pyrido[3,2- d ]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth